<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05480072</url>
  </required_header>
  <id_info>
    <org_study_id>2022P001440</org_study_id>
    <nct_id>NCT05480072</nct_id>
  </id_info>
  <brief_title>Endocannabinoids, Stress, Craving And Pain Effects (ESCAPE) Study</brief_title>
  <official_title>Investigating the Effects of Palmitoylethanolamide (PEA) on Stress, Craving and Pain in Opioid Use Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Opioid use disorder (OUD) represents one of the most severe public health crises, with more&#xD;
      than 2 million individuals affected in the United States. Existing treatments do not target&#xD;
      and restore several key alterations triggering opioid craving and relapse, including&#xD;
      increased response to stress, mood disturbances and greater sensitivity to pain, which are&#xD;
      caused by prolonged exposure to opioids. This double-blind, randomized, placebo-controlled&#xD;
      study will investigate the effects that palmitoylethanolamide (PEA), an endogenous molecule&#xD;
      part of the endocannabinoid system available as a dietary supplement, exerts on these&#xD;
      alterations and their underlying mechanisms, with the goal of identifying a novel therapeutic&#xD;
      approach to reduce craving and prevent relapse in patients with OUD.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2022</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">August 2024</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>stress-induced opioid craving</measure>
    <time_frame>day 21</time_frame>
    <description>changes from baseline in experimentally-provoked stress-induced craving ratings</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Opioid Use Disorder</condition>
  <arm_group>
    <arm_group_label>PEA 600 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PEA capsules(600 mg twice a day) will be administered for 21 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsules(600 mg twice a day) will be administered for 21 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palmitoylethanolamide</intervention_name>
    <description>Palmitoyethanolamide (PEA) s a dietary supplement with anti-inflammatory and analgesic properties. Subjects will receive PEA (Levagen+) 600 capsules mg twice daily (BID) orally from Day 1 to Day 21</description>
    <arm_group_label>PEA 600 mg</arm_group_label>
    <other_name>Levagen+</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will receive placebo matched to 600 mg PEA (Levagen+) capsules BID orally from Day 1 to Day 21</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of OUD&#xD;
&#xD;
          -  Fluent in English&#xD;
&#xD;
          -  Receiving either buprenorphine or methadone for treatment of opioid use disorder for&#xD;
             at least 3 consecutive months prior to enrollment&#xD;
&#xD;
          -  Agreeable to abstaining from using any cannabis or cannabidiol (CBD)-containing&#xD;
             products for the duration of the trial&#xD;
&#xD;
          -  For women of childbearing potential: agreeable to use one of the following:&#xD;
&#xD;
               -  hormonal methods, such as birth control pills, patches, injections, vaginal&#xD;
                  rings, or implants&#xD;
&#xD;
               -  barrier methods (such as a condom or diaphragm) used with a spermicide (a foam,&#xD;
                  cream, or gel that kills sperm)&#xD;
&#xD;
               -  intrauterine device (IUD)&#xD;
&#xD;
               -  abstinence (no sex)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current diagnosis of moderate-to-severe cannabis use disorder and/or alcohol use&#xD;
             disorder&#xD;
&#xD;
          -  History of psychotic and schizoaffective disorders&#xD;
&#xD;
          -  Currently pregnant or breastfeeding (female only)&#xD;
&#xD;
          -  History of autoimmune or chronic inflammatory diseases&#xD;
&#xD;
          -  Current use of medications known to alter inflammatory and immune response&#xD;
&#xD;
          -  BMI &gt;40&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Ancella Roy</last_name>
      <phone>617-732-5935</phone>
      <email>aroy19@bwh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Primavera A Spagnolo, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2022</verification_date>
  <study_first_submitted>July 27, 2022</study_first_submitted>
  <study_first_submitted_qc>July 27, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">July 29, 2022</study_first_posted>
  <last_update_submitted>July 27, 2022</last_update_submitted>
  <last_update_submitted_qc>July 27, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Primavera A. Spagnolo, MD, PhD</investigator_full_name>
    <investigator_title>Assistant Professor/ Research Scientist</investigator_title>
  </responsible_party>
  <keyword>palmitoylethanolamide</keyword>
  <keyword>stress</keyword>
  <keyword>craving</keyword>
  <keyword>pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Palmidrol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

